See more : Texhoma Energy, Inc. (TXHE) Income Statement Analysis – Financial Results
Complete financial analysis of IQVIA Holdings Inc. (0JDM.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IQVIA Holdings Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Solar Industries India Limited (SOLARINDS.BO) Income Statement Analysis – Financial Results
- Welsbach Technology Metals Acquisition Corp. (WTMAR) Income Statement Analysis – Financial Results
- PACCAR Inc (PAE.DE) Income Statement Analysis – Financial Results
- Xemex Group, Inc. (XMEX) Income Statement Analysis – Financial Results
- Discovery Silver Corp. (DSVSF) Income Statement Analysis – Financial Results
IQVIA Holdings Inc. (0JDM.L)
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.98B | 14.41B | 13.87B | 11.36B | 11.09B | 10.41B | 9.74B | 6.88B | 5.74B | 5.46B | 5.10B | 4.87B | 4.33B | 3.92B |
| Cost of Revenue | 9.75B | 9.38B | 9.23B | 7.50B | 7.30B | 6.75B | 6.30B | 4.75B | 4.14B | 3.98B | 3.76B | 3.63B | 3.19B | 2.80B |
| Gross Profit | 5.24B | 5.03B | 4.64B | 3.86B | 3.79B | 3.67B | 3.44B | 2.13B | 1.60B | 1.48B | 1.34B | 1.23B | 1.14B | 1.12B |
| Gross Profit Ratio | 34.96% | 34.89% | 33.45% | 33.97% | 34.16% | 35.21% | 35.30% | 30.94% | 27.90% | 27.14% | 26.22% | 25.34% | 26.39% | 28.52% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.34M | 0.00 | 4.96M | 10.43M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.72B | 1.61B | 1.01B | 920.99M | 882.34M | 860.51M | 803.26M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.80M | 14.50M | 0.00 | 0.00 |
| SG&A | 2.05B | 2.07B | 1.96B | 1.79B | 1.73B | 1.72B | 1.61B | 1.01B | 920.99M | 882.34M | 860.51M | 817.76M | 762.30M | 698.41M |
| Other Expenses | 0.00 | 1.13B | 1.26B | 1.29B | 1.20B | -5.00M | -30.00M | 8.00M | -2.36M | 8.98M | 185.00K | 3.57M | -9.07M | -15.65M |
| Operating Expenses | 2.05B | 3.20B | 3.23B | 3.08B | 2.94B | 2.86B | 2.62B | 1.30B | 920.99M | 882.34M | 860.51M | 817.76M | 762.30M | 698.41M |
| Cost & Expenses | 13.01B | 12.58B | 12.46B | 10.58B | 10.24B | 9.60B | 8.92B | 6.05B | 5.06B | 4.86B | 4.62B | 4.45B | 3.95B | 3.50B |
| Interest Income | 36.00M | 13.00M | 6.00M | 6.00M | 9.00M | 8.00M | 7.00M | 4.00M | 4.32M | 3.41M | 3.94M | 3.07M | 3.94M | 3.80M |
| Interest Expense | 672.00M | 416.00M | 375.00M | 416.00M | 447.00M | 414.00M | 346.00M | 144.00M | 101.79M | 100.59M | 123.51M | 134.37M | 109.07M | 141.43M |
| Depreciation & Amortization | 1.13B | 1.13B | 1.26B | 1.29B | 1.20B | 1.14B | 1.01B | 289.00M | 127.74M | 121.01M | 107.50M | 98.29M | 92.00M | 84.22M |
| EBITDA | 3.26B | 2.89B | 2.75B | 2.06B | 1.88B | 1.88B | 1.65B | 906.00M | 756.20M | 711.37M | 541.55M | 500.09M | 385.74M | 467.37M |
| EBITDA Ratio | 21.73% | 20.38% | 20.28% | 18.85% | 18.94% | 18.76% | 18.59% | 16.41% | 14.11% | 13.42% | 11.53% | 10.69% | 10.78% | 12.57% |
| Operating Income | 1.98B | 1.80B | 1.39B | 731.00M | 777.00M | 741.00M | 719.00M | 642.00M | 646.61M | 590.39M | 462.33M | 396.44M | 345.25M | 395.01M |
| Operating Income Ratio | 13.19% | 12.48% | 10.04% | 6.44% | 7.01% | 7.12% | 7.38% | 9.33% | 11.27% | 10.81% | 9.07% | 8.15% | 7.98% | 10.07% |
| Total Other Income/Expenses | -518.00M | -436.00M | -265.00M | -358.00M | -425.00M | -413.00M | -371.00M | -97.00M | -107.01M | -87.81M | -139.22M | -129.01M | -196.89M | -153.28M |
| Income Before Tax | 1.46B | 1.36B | 1.13B | 373.00M | 352.00M | 328.00M | 331.00M | 479.00M | 539.00M | 502.19M | 323.12M | 267.43M | 184.68M | 241.73M |
| Income Before Tax Ratio | 9.74% | 9.46% | 8.13% | 3.28% | 3.17% | 3.15% | 3.40% | 6.96% | 9.39% | 9.20% | 6.34% | 5.50% | 4.27% | 6.16% |
| Income Tax Expense | 101.00M | 260.00M | 163.00M | 72.00M | 116.00M | 59.00M | -987.00M | 345.00M | 158.99M | 150.06M | 95.97M | 93.36M | 15.11M | 77.58M |
| Net Income | 1.36B | 1.09B | 966.00M | 279.00M | 191.00M | 259.00M | 1.31B | 115.00M | 387.21M | 356.38M | 226.59M | 177.55M | 241.77M | 160.60M |
| Net Income Ratio | 9.06% | 7.57% | 6.96% | 2.46% | 1.72% | 2.49% | 13.44% | 1.67% | 6.75% | 6.53% | 4.44% | 3.65% | 5.59% | 4.09% |
| EPS | 7.39 | 5.82 | 5.05 | 1.46 | 0.98 | 1.27 | 6.01 | 0.77 | 3.15 | 2.78 | 1.83 | 1.42 | 1.93 | 1.28 |
| EPS Diluted | 7.29 | 5.72 | 4.95 | 1.43 | 0.96 | 1.24 | 5.88 | 0.76 | 3.08 | 2.72 | 1.77 | 1.39 | 1.90 | 1.26 |
| Weighted Avg Shares Out | 183.80M | 187.60M | 191.40M | 191.30M | 195.10M | 203.70M | 217.80M | 149.10M | 123.04M | 127.99M | 124.15M | 125.47M | 125.47M | 125.47M |
| Weighted Avg Shares Out (Dil) | 186.30M | 190.60M | 195.00M | 195.00M | 199.60M | 208.20M | 222.60M | 152.00M | 125.63M | 131.08M | 127.86M | 127.55M | 127.55M | 127.55M |
Source: https://incomestatements.info
Category: Stock Reports